Linked Life Data

17252252

Source:http://linkedlifedata.com/resource/pubmed/id/17252252

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-4-11
pubmed:abstractText
Patients on anticoagulants of the vitamin K antagonist type may sometimes be scheduled for invasive procedures or surgical operations. In order to minimize the risk of thromboembolism caused by the interruption of chronic anticoagulation for the procedure, temporary administration of anticoagulants with shorter half-lives is required (so-called bridging anticoagulation). The present review outlines the spectrum of risks during this period regarding both thromboembolism and major bleeding. Low molecular weight heparins may be considered the medication of choice for bridging anticoagulation, mainly for practical reasons. Since they require no coagulation monitoring or dose adjustment, outpatient treatment is feasible. Such heparins are not labelled for the indication of bridging anticoagulation. However, based on recent studies of large patient cohorts, evidence of their efficacy and safety is significantly more solid than for unfractionated heparin. A simple dosing scheme for low molecular weight heparins is given here and all requirements are discussed for safe guidance through episodes of bridging anticoagulation.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0009-4722
pubmed:author
pubmed:issnType
Print
pubmed:volume
78
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-6, 128-32
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
[Bridging anticoagulation].
pubmed:affiliation
Arbeitsbereich Angiologie, Medizinische Klinik III, Universitätsklinikum Carl Gustav Carus,Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden. sebastian.schellong@uniklinikum-dresden.de
pubmed:publicationType
Journal Article, Comparative Study, English Abstract, Review